{"id":"NCT00707031","sponsor":"Sanofi","briefTitle":"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","officialTitle":"A Randomized, Open-label, Active-controlled, 2-arm Parallel-group, Multicenter 24-week Study Followed by an Extension Assessing the Efficacy and Safety of AVE0010 Versus Exenatide on Top of Metformin in Patients With Type 2 Diabetes Not Adequately Controlled With Metformin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-06","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2008-06-30","resultsPosted":"2016-10-11","lastUpdate":"2016-12-02"},"enrollment":639,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Lixisenatide (AVE0010)","otherNames":[]},{"type":"DEVICE","name":"Pen auto-injector","otherNames":["OptiClik速"]},{"type":"DRUG","name":"Exenatide","otherNames":["Byetta速"]},{"type":"DEVICE","name":"Prefilled pen injector","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]}],"arms":[{"label":"Lixisenatide","type":"EXPERIMENTAL"},{"label":"Exenatide","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) in comparison to exenatide (Byetta速), as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.\n\nThe primary objective is to assess the effects of lixisenatide in comparison to exenatide (Byetta速), as an add-on treatment to metformin, on glycemic control in terms of glycosylated hemoglobin (HbA1c) reduction (absolute change) at Week 24.\n\nThe secondary objectives are to assess the effects of lixisenatide on percentage of patients reaching HbA1c less than 7 percent (%) or HbA1c less than or equal to (\\<=) 6.5%, fasting plasma glucose (FPG), body weight; to evaluate safety, tolerability and to assess the impact of gastrointestinal tolerance on quality of life (QoL) (patient assessment of upper gastrointestinal disorders - quality of life \\[PAGI-QOL\\]).","primaryOutcome":{"measure":"Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Lixisenatide","deltaMin":-0.79,"sd":0.053},{"arm":"Exenatide","deltaMin":-0.96,"sd":0.054}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":25},"locations":{"siteCount":18,"countries":["United States","Argentina","Austria","Brazil","Colombia","Denmark","Finland","Germany","Greece","Hungary","Italy","Netherlands","Norway","Poland","Puerto Rico","Russia","Spain","Sweden"]},"refs":{"pmids":["23698396","39963952"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":26,"n":318},"commonTop":["Nausea","Diarrhoea","Vomiting","Nasopharyngitis","Headache"]}}